- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Hyperparathyroidism, Secondary, Kidney Disease, Secondary Hyperparathyroidism
- Interventions
- cinacalcet capsule, placebo, Standard of Care
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 1,999
matching trials from the live ClinicalTrials.gov search.
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity, Attention Deficit Hyper Activity
- Interventions
- CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose), Placebo
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 24
- States / cities
- Jacksonville, Florida • Maitland, Florida • Orlando, Florida + 21 more
- Conditions
- Dry Eye Disease
- Interventions
- Intense pulsed light with C.STIM device
- Device
- Lead sponsor
- Quantel Medical
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Lexington, Kentucky • Raleigh, North Carolina • Nashville, Tennessee + 1 more
- Conditions
- Congenital Hemophilia A
- Interventions
- rVIII-SingleChain
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- Up to 11 Years · Male only
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Chicago, Illinois
- Conditions
- Melasma
- Interventions
- PiQo4
- Device
- Lead sponsor
- Focus Medical, LLC
- Industry
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Iron Deficiency Anaemia, Chronic Kidney Disease
- Interventions
- FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, Oral Iron (Ferrous sulphate)
- Drug
- Lead sponsor
- Vifor Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 626 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Wilmington, North Carolina
- Conditions
- Suicide Prevention, Suicide Safety Planning, Suicidal Ideation, Suicide Attempt
- Interventions
- Local Care Continuity, Centralized Care Navigation
- Behavioral
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 176,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 1
- States / cities
- Pleasanton, California
- Conditions
- Pulmonary Embolism
- Interventions
- Adient absorbable filter + best practice VTE prophylaxis, best practice VTE prophylaxis
- Device
- Lead sponsor
- Adient Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 854 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Indianapolis, Indiana
- Conditions
- Muscle Stimulation, Abdominal Fat
- Interventions
- Brera
- Device
- Lead sponsor
- Cynosure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Westford, Massachusetts
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type
- Interventions
- Placebo, AVP-786
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 601 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 93
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 68 more
- Conditions
- Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma
- Interventions
- Nivolumab, Azacitidine, Post Treatment Surgery
- Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- Up to 39 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 19 more
- Conditions
- Scars
- Interventions
- SLI-F06, Formulation buffer
- Drug
- Lead sponsor
- Scarless Laboratories, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • St Louis, Missouri • Bala-Cynwyd, Pennsylvania
- Conditions
- Venous Thromboembolism
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
- Conditions
- Geographic Atrophy, Age-Related Macular Degeneration
- Interventions
- K8
- Drug
- Lead sponsor
- Inflammasome Therapeutics
- Industry
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 9
- States / cities
- Loma Linda, California • Lexington, Kentucky • Portland, Maine + 6 more
- Conditions
- Cataract, Corneal Astigmatism
- Interventions
- IOL Model ZFR00V, IOL Model ZCB00
- Device
- Lead sponsor
- Johnson & Johnson Surgical Vision, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 15
- States / cities
- Bakersfield, California • Torrance, California • West Palm Beach, Florida + 12 more
- Conditions
- Dental Pain
- Interventions
- Oxycodone, Buprenorphine, Placebo Film, Placebo Capsule
- Drug
- Lead sponsor
- BioDelivery Sciences International
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 3
- States / cities
- Austin, Texas • San Marcos, Texas • Salt Lake City, Utah
- Conditions
- Asthma
- Interventions
- tiotropium 5mcg/day, placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Los Angeles, California • Riverside, California + 16 more
- Conditions
- Spondylitis, Ankylosing
- Interventions
- Ixekizumab, Placebo, Adalimumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Upland, California + 31 more
- Conditions
- Celiac Disease
- Interventions
- ALV003, placebo
- Drug
- Lead sponsor
- Alvine Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 79
- States / cities
- Decatur, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 70 more
- Conditions
- Hand Eczema
- Interventions
- Ruxolitinib cream, Vehicle
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Encino, California • Fountain Valley, California + 22 more
- Conditions
- Complicated Urinary Tract Infections
- Interventions
- Ceftazidime -avibactam, Cefepime
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 3 Months to 17 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 3
- States / cities
- San Diego, California • Winston-Salem, North Carolina • Toledo, Ohio
- Conditions
- Breast Cancer, Renal Cell Carcinoma
- Interventions
- IPI-549 (eganelisib), Atezolizumab, nab-paclitaxel, Bevacizumab
- Drug
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 24
- States / cities
- Chandler, Arizona • Tucson, Arizona • Fullerton, California + 20 more
- Conditions
- Crohn's Disease
- Interventions
- Brodalumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- Not listed
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Jacksonville, Florida • Hammond, Louisiana + 8 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- dextromethorphan HBr and quinidine sulfate
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Fort Lauderdale, Florida • Gainesville, Florida